Collaborations & Alliances

Janssen Biotech, Amgen in Clinical and Supply Pact

To evaluate immunotherapy DARZALEX in combination with KYPROLIS in cancer

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Janssen Biotech has entered into a master clinical trial collaboration and supply agreement with Onyx Pharmaceuticals, Inc., a subsidiary of Amgen, to evaluate the efficacy and safety of CD38-directed immunotherapy daratumumab (DARZALEX) in combination with a proteasome inhibitor (PI) carfilzomib (KYPROLIS) and dexamethasone. The agreement covers all potential opportunities for combining daratumumab and carfilzomib to treat cancer. Janssen licensed daratumumab from Genmab and is responsible for ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters